Onyx receives FDA Standard Review designation for carfilzomib NDA to treat RRMM

		Cancer Friends Network > Types of Cancer > Extrahepatic Bile Duct Cancer
Onyx receives FDA Standard Review designation for carfilzomib NDA to treat RRMM

LinkBack

Thread Tools

Display Modes

#1 (permalink)

01-11-2012, 02:30 AM

cancerfr

Administrator

Join Date: Sep 2008

Posts: 47,390

Onyx receives FDA Standard Review designation for carfilzomib NDA to treat RRMM

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Standard Review designation to the New Drug Application (NDA) for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma.

Tim Pearson

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Trackbacks are On Pingbacks are On Refbacks are On Forum Rules

All times are GMT. The time now is 09:50 AM.

CancerFriends.net